Novo Nordisk Stock Falls After Weight Loss Drug Data

Novo Nordisk's stock dropped significantly after new data showed its experimental weight-loss drug Cagrisema was less effective than Eli Lilly's tirzepatide.

Post Share

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

berlingskeDanish48d ago

Novo Nordisk-aktie falder efter ny data om vægttabshåb

Cagrisema viser et lavere vægttab end Eli Lillys aktive stof tirzepatid i et nyt studie. Novo-aktien falder.

Read full article →

PERSPECTA

PERSPECTA

Novo Nordisk Stock Falls After Weight Loss Drug Data

Sources

Novo Nordisk-aktie falder efter ny data om vægttabshåb

Related Stories

Amazon's First Customer Receipt Goes Viral, Bezos and Musk React

Truck Carrying Undeclared Fuel Seized at Tabaco Port, Philippines

Philippines Affirms Sovereign Rights in Oil Exploration Agreements

Philippines Assures Adherence to Laws in Joint Oil Exploration Talks

PERSPECTA